Drugs/Pharmaceuticals

Page 1 of 2812345...1020...Last »

FDA clears Roche high-volume immunoassay lab testing solution to support critical medical treatment decisions

PR Newswire — May 1, 2017 INDIANAPOLIS, May 1, 2017 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its new, dedicated high-volume testing immunoassay solution for the cobas 8000 modular analyzer series, the cobas e 801 module,... (Continue reading)

Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival

PR Newswire — March 20, 2017 INDIANAPOLIS, March 20, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated... (Continue reading)

AB BioTechnologies selects Vanrx Pharmasystems aseptic filling and lyophilizer loading workcells

PR Newswire — March 7, 2017 BLOOMINGTON, IN, March 7, 2017 /PRNewswire/ – AB BioTechnologies (AB), a provider of contract development and manufacturing services for the pharmaceutical industry, has selected Vanrx Pharmasystems to provide aseptic filling and lyophilizer loading systems... (Continue reading)

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly’s Taltz (ixekizumab) Compared to Stelara (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

PR Newswire — March 4, 2017 Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS, March 4, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)... (Continue reading)

Lilly Completes Acquisition of CoLucid Pharmaceuticals

PR Newswire — March 1, 2017 INDIANAPOLIS, March 1, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock... (Continue reading)

Lilly to Present New Data for Taltz (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting

PR Newswire — February 28, 2017 INDIANAPOLIS, Feb. 28, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz┬« (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the... (Continue reading)

Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo

PR Newswire — February 15, 2017 INDIANAPOLIS, Feb. 15, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of baricitinib in the... (Continue reading)

Lilly To Present At Leerink Partners Global Healthcare Conference

PR Newswire — February 9, 2017 INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique Conterno, senior vice president of Lilly and... (Continue reading)

Lilly to Present at Cowen Health Care Conference

PR Newswire — February 8, 2017 INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017. David A. Ricks, Lilly’s president... (Continue reading)

Lilly’s Trulicity (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes

PR Newswire — February 8, 2017 INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ — The label for Eli Lilly and Company’s (NYSE: LLY) once-weekly Trulicity┬« (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2... (Continue reading)

Page 1 of 2812345...1020...Last »